Rodman & Renshaw Reiterates Oncothyreon Market Outperform, $10 PT

Rodman & Renshaw reiterated its Oncothyreon ONTY Market Outperform rating and $10 price target in a research report published today. In the report, Rodman & Renshaw states, "We believe that the promising Phase 2 data for Stimuvax establishes the potential for success in two ongoing Phase 3 trials, with a potentially transformative interim analysis readout expected by 1Q12 that could generate substantial value for shareholders." Shares of Oncothyreon closed today at $6.46, up 4.36% from Wednesday's market close.